Total therapy-based treatment for multiple myeloma—a single center experience

Magen-Nativ, Hila; Ram, Ron; Yeshurun, Moshe; Gafter-Gvili, Anat; Raanani, Pia; Shpilberg, Ofer
January 2010
Annals of Hematology;Jan2010, Vol. 89 Issue 1, p53
Academic Journal
Incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma. For the last 4 years we have adopted the more intensified approach, previously published as total therapy 3 by the Arkansas group and used it with local modifications. This study aims to evaluate the efficacy and safety of the Arkansas protocol-based treatment outside clinical trial in a tertiary medical center in Israel. We retrospectively analyzed 23 patients. Seventy-three percent of the patients achieved very good partial remission (VGPR) before autologous stem cell transplantation (ASCT). Eighty-six percent of the patients achieved at least VGPR after tandem ASCT. Two-year overall survival was estimated as 70%. Four patients died during treatment, one as a result of disease progression. We conclude that this protocol is effective and rather safe. Further clinical trials should assess which subgroups of patients would benefit most from this approach.


Related Articles

  • Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Micallef, I. N. M.; Ho, A. D.; Klein, L. M.; Marulkar, S.; Gandhi, P. J.; McSweeney, P. A. // Bone Marrow Transplantation;Mar2011, Vol. 46 Issue 3, p350 

    Lenalidomide and other new agents have considerable activity in multiple myeloma (MM) and have changed the landscape of treatment. Data suggest that lenalidomide therapy before autologous hematopoietic stem cell transplantation has a detrimental effect on stem cell mobilization. This...

  • New England Journal of Medicine Reports on Three Phase III REVLIMID(r) (lenalidomide) Trials in Patients with Newly Diagnosed Multiple Myeloma.  // Biomedical Market Newsletter;5/12/2012, Vol. 21, p1 

    The article informs that phase III clinical trials of REVLIMID, lenalidomide drug, from Celgene Corp. were published online in the May 10, 2012 edition of the New England Journal of Medicine. It provides information that phase III clinical trials were performed to evaluate the use of continuous...

  • Future challenges. Sirohi, B.; Powles, R. // Bone Marrow Transplantation;Dec2007, Vol. 40 Issue 12, p1157 

    Treatment for patients with myeloma has changed unrecognisably over the last two decades and now includes a sequence of treatments including chemotherapy, biological targeted therapy with or without consideration for high-dose therapy (autologous and allogeneic stem cell transplantation for...

  • NCI Reports Revlimid Post-SCT Results Positive; Trial Stopped. Young, Donna // BioWorld Today;12/21/2009, Vol. 20 Issue 244, p1 

    The article deals with the preliminary results from a National Cancer Institute (NCI)-sponsored Phase III trial on Celgene Corporation's Revlimid as maintenance lenalidomide therapy for patients with multiple myeloma, in December 2009. Details of the CALGB 100104/ECOG 100104 trial are presented....

  • The lymphoma-like polychemotherapy regimen 'Dexa-BEAM' in advanced and extramedullary multiple myeloma. Rasche, Leo; Strifler, Susanne; Duell, Johannes; Rosenwald, Andreas; Buck, Andreas; Maeder, Uwe; Einsele, Hermann; Knop, Stefan // Annals of Hematology;Jul2014, Vol. 93 Issue 7, p1207 

    Extramedullary disease (EMD) in multiple myeloma (MM) is characterised by an aggressive biology and an adverse prognosis especially when occurring at relapse. Due to the high proliferation found in EMD lesions, we analysed outcome data of patients treated with a lymphoma-type therapy not based...

  • Treatment Strategies in Elderly Patients with Multiple Myeloma. Hang Quach; Prince, H. Miles; Mileshkin, Linda // Drugs & Aging;2007, Vol. 24 Issue 10, p829 

    Multiple myeloma (MM), a plasma cell malignancy, is a disorder of the elderly with an increasing prevalence as the average life expectancy increases. Survival remains unacceptably low in elderly patients with MM, in whom the gold standard of treatment has been, until recently, oral melphalan and...

  • Long-term Results of Response to Therapy, Time to Progression, and Survival With Lenalidomide Plus Dexamethasone in Newly Diagnosed Myeloma. Lacy, Martha Q.; Gertz, Morie A.; Dispenzieri, Angela; Hayman, Suzanne R.; Geyer, Susan; Kabat, Brian; Zeldenrust, Steven R.; Kumar, Shaji; Greipp, Philip R.; Fonseca, Rafael; Lust, John A.; Russell, Stephen J.; Kyle, Robert A.; Witzig, Thomas E.; Bergsagel, P. Leif; Stewart, A. Keith; Rajkumar, S. Vincent // Mayo Clinic Proceedings;Oct2007, Vol. 82 Issue 10, p1179 

    OBJECTIVE: To determine the long-term effects of a combined regimen of lenalldomide and dexamethasone (Rev-Dex) on time to progression, progression-free survival, and overall survival (OS) in patients with multiple myeloma. PATIENTS AND METHODS: From March 2004 through October 2004, 34 patients...

  • High-dose chemotherapy in multiple myeloma. Goldschmidt, H.; Hegenbart, U.; Wallmeier, M.; Moos, M.; Haas, R. // Leukemia (08876924);Dec97 Supplement 5, Vol. 11, pS27 

    The median survival of conventionally treated patients with multiple myeloma is 3 years. Modifications of conventional chemotherapy have failed to show an improved survival rate in most randomized trials. Therapy regimens with dose-escalated alkylating agents (ie melphalan) have induced higher...

  • New drugs may change the role of transplant in treatment of myeloma. Levitan, Dave // Hem/Onc Today;8/25/2009, Vol. 10 Issue 16, p1 

    This article reports that improving response rates with novel agents have raised a question about the use of stem cell transplant or the urgency to use the procedure as a front-line therapy in patients with multiple myeloma.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics